Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece.

The analysis, conducted in the REDUCE-IT placebo arm, evaluated risk-weighted apolipoprotein B (RW-apoB), an integrated metric designed to reflect the relative atherogenicity of apoB-containing lipoproteins. Among statin-treated patients with elevated triglycerides (TG) , RW-apoB was found to more effectively identify individuals at increased residual cardiovascular (CV) risk compared with traditional lipid biomarkers.

Residual cardiovascular risk remains a well-recognized challenge in statin-treated patients, particularly among those with elevated TGs despite controlled low-density lipoprotein cholesterol (LDL-C) levels.

Across 3,485 participants in the REDUCE-IT placebo arm followed for a median of 4.9 years and with lipid measurements available, RW-apoB levels were on average calculated to be approximately 30% higher than measured apoB, suggesting potential underrecognition of lipid-associated residual risk. RW-apoB demonstrated superior risk prediction for cardiovascular outcomes in this statin-treated population compared with LDL-C, non-HDL-C, and apoB.

In addition, application of European Society of Cardiology (ESC)-defined intervention thresholds identified a greater proportion of patients at elevated risk when using RW-apoB compared with apoB alone, supporting its potential role in improving risk stratification in routine clinical settings.

"The findings presented at EAS build on some of our prior work demonstrating that apoB-containing lipoproteins do not contribute equally to atherosclerotic riski," said Michaela B. Rehman, Cardiology Department, Ramsay Santé, Médipôle Lyon-Villeurbanne, Villeurbanne, France and lead author of the analysis. "By incorporating the relative atherogenicity of triglyceride-rich lipoproteins and lipoprotein(a), risk-weighted apoB provides a more integrated assessment of lipid-related risk. These results extend earlier research and suggest that this approach may help identify statin-treated patients who remain at elevated cardiovascular risk and may benefit from additional intervention."

Risk-weighted apoB is calculated by assigning differential weights to lipid components, including triglyceride-rich lipoproteins and lipoprotein(a), which have been shown to be 4-5 and 6–7 times, respectively, more atherogenic per particle than LDL, thereby providing a more accurate reflection of the total atherogenic burden and coronary heart disease risk.

"As a reminder, findings from the REDUCE-IT trial previously demonstrated that treatment with icosapent ethyl significantly reduced major adverse cardiovascular events in high-risk, statin-treated patients with elevated triglycerides," said Deepak L. Bhatt, MD, MPH, MBA, Director of the Mount Sinai Fuster Heart Hospital at the Icahn School of Medicine at Mount Sinai in New York and Principal Investigator of REDUCE-IT. "Importantly, ongoing analyses continue to enhance understanding of residual risk and inform approaches to improving patient identification and management."

These insights, together with recent guideline updates, have supported the evolving role of icosapent ethyl (IPE) in contemporary lipid management. The 2025 focused update to the ESC/EAS dyslipidemia guidelines included high-dose IPE among recommended therapies for high- and very high-risk patients based on the REDUCE-IT evidence base. More recently, the 2026 ACC/AHA/Multisociety guideline update further characterizes the clinical role of IPE in reducing CV risk in statin-treated patients with elevated TGs, reinforcing its relevance in addressing an important medical need for the millions of patients with persistent cardiovascular risk.